BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38372948)

  • 1. Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.
    Li X; Su H; Tang W; Shu S; Zhao L; Sun J; Fan H
    Invest New Drugs; 2024 Apr; 42(2):185-195. PubMed ID: 38372948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
    Xue W; Wang T; Tian WJ; Pang SQ; Zhang HF; Jia WD
    Curr Med Sci; 2024 Feb; 44(1):168-179. PubMed ID: 38217831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
    Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
    J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
    Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
    Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA LEF1-AS1 silencing diminishes EZH2 expression to delay hepatocellular carcinoma development by impairing CEBPB-interaction with CDCA7.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    Cell Cycle; 2020 Apr; 19(8):870-883. PubMed ID: 32178558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of association of OCT4 with LEF1 expression in esophageal squamous cell carcinoma and their impact on epithelial-mesenchymal transition, invasion, and migration.
    Zhao Y; Li C; Huang L; Niu S; Lu Q; Gong D; Huang S; Yuan Y; Chen H
    Cancer Med; 2018 Aug; 7(8):3977-3987. PubMed ID: 29974668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
    Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
    Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repression of WT1-Mediated LEF1 Transcription by Mangiferin Governs β-Catenin-Independent Wnt Signalling Inactivation in Hepatocellular Carcinoma.
    Tan HY; Wang N; Li S; Hong M; Guo W; Man K; Cheng CS; Chen Z; Feng Y
    Cell Physiol Biochem; 2018; 47(5):1819-1834. PubMed ID: 29953980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
    Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
    Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-621 functions as a metastasis suppressor in colorectal cancer by directly targeting LEF1 and suppressing Wnt/β-catenin signaling.
    Chen X; Tu J; Liu C; Wang L; Yuan X
    Life Sci; 2022 Nov; 308():120941. PubMed ID: 36087740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
    Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
    Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis.
    Zhang JN; Wei F; Lei LH; Yang Y; Yang Y; Zhou WP
    Bioengineered; 2021 Dec; 12(2):11728-11739. PubMed ID: 34784846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells.
    Ao J; Chiba T; Shibata S; Kurosugi A; Qiang N; Ma Y; Kan M; Iwanaga T; Sakuma T; Kanzaki H; Kanayama K; Kojima R; Kusakabe Y; Nakamura M; Saito T; Nakagawa R; Kondo T; Ogasawara S; Suzuki E; Muroyama R; Kato J; Mimura N; Kanda T; Maruyama H; Kato N
    Biochem Biophys Res Commun; 2021 Apr; 549():171-178. PubMed ID: 33676186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrin subunit beta 8 contributes to lenvatinib resistance in HCC.
    Hou W; Bridgeman B; Malnassy G; Ding X; Cotler SJ; Dhanarajan A; Qiu W
    Hepatol Commun; 2022 Jul; 6(7):1786-1802. PubMed ID: 35238496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal adhesion kinase confers lenvatinib resistance in hepatocellular carcinoma via the regulation of lysine-deficient kinase 1.
    Hou W; Gad SA; Ding X; Dhanarajan A; Qiu W
    Mol Carcinog; 2024 Jan; 63(1):173-189. PubMed ID: 37787401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network Pharmacology-Based Strategy to Investigate the Mechanisms of Lenvatinib in the Treatment of Hepatocellular Carcinoma.
    Liu P; Han B; Zhang Y; Wang X
    Comput Intell Neurosci; 2022; 2022():7102500. PubMed ID: 35720901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma.
    Huang S; Ma Z; Zhou Q; Wang A; Gong Y; Li Z; Wang S; Yan Q; Wang D; Hou B; Zhang C
    Int J Biol Sci; 2022; 18(11):4357-4371. PubMed ID: 35864956
    [No Abstract]   [Full Text] [Related]  

  • 20. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
    He X; Hikiba Y; Suzuki Y; Nakamori Y; Kanemaru Y; Sugimori M; Sato T; Nozaki A; Chuma M; Maeda S
    Sci Rep; 2022 May; 12(1):8007. PubMed ID: 35568782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.